









Markets
/
Stocks
/
nasdaq-vrna
/

Verona Pharma PLC

VRNA

106.910USD

0.000

Close 10/30, 16:00（ET）Quotes delayed by 15 min

73.55BMarket Cap

LossP/E TTM



Verona Pharma PLC

106.910

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Verona Pharma PLC

Currency: USD Updated: 2025-10-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals.

Verona Pharma PLC's Score

Industry at a Glance

Industry Ranking

43 / 503

Overall Ranking

112 / 4702

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

106.222

Target Price

-0.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Verona Pharma PLC Highlights

StrengthsRisks

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 8806.12% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 33.09M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 143.53.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 78.50M shares, decreasing 5.21% quarter-over-quarter.

Held by Stanley Druckenmiller

Star Investor Stanley Druckenmiller holds 1.00M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.00.

Financial Health

Currency: USD Updated: 2025-10-07

The company's current financial score is 9.08, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.08

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Verona Pharma PLC's Company Valuation

Currency: USD Updated: 2025-10-07

The company’s current valuation score is 7.48, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is 0.00, which is NaN% below the recent high of 0.00 and +Inf% above the recent low of -1125.49.

Score

Industry at a Glance

Previous score

7.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/503

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-07

The company’s current earnings forecast score is 6.17, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Verona Pharma PLC is 107.00, with a high of 107.00 and a low of 100.00.

Score

Industry at a Glance

Previous score

6.17

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-07

The company’s current price momentum score is 6.69, which is lower than the Biotechnology & Medical Research industry's average of 7.01.

Score

Industry at a Glance

Previous score

7.96

Change

-1.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-13.724

Sell

RSI(14)

1.038

Oversold

STOCH(KDJ)(9,3,3)

47.344

Sell

ATR(14)

7.807

High Vlolatility

CCI(14)

-466.667

Oversold

Williams %R

100.000

Oversold

TRIX(12,20)

-0.330

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

85.468

Buy

MA10

96.043

Buy

MA20

101.167

Buy

MA50

103.829

Buy

MA100

97.404

Buy

MA200

78.449

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-07

The latest institutional shareholding proportion is 91.09%, representing a quarter-over-quarter decrease of 5.29%. The largest institutional shareholder is PRFDX, holding a total of 1.79M shares, representing 2.08% of shares outstanding, with 7.34% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

6.13M

+11.19%

Perceptive Advisors LLC

5.51M

-16.09%

Darwin Global Management Ltd

4.13M

+5.26%

Frazier Life Sciences Management, L.P.

3.38M

-2.14%

Ali (Behbahani)

3.19M

RTW Investments L.P.

3.05M

+7.13%

Eventide Asset Management, LLC

2.72M

-6.16%

Goldman Sachs & Company, Inc.

2.61M

+152.32%

New Enterprise Associates (NEA)

2.26M

-15.82%

Summit Partners Public Asset Management, LLC

2.14M

-7.70%

Risk Assessment

Currency: USD Updated: 2025-10-07

The company’s current risk assessment score is 7.01, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.